'Pa­tients are not a com­pa­ny's re­source': FDA can­cer czar Richard Paz­dur has a bone to pick with the top R&D ex­ecs in can­cer

If there’s one law in on­col­o­gy R&D, it’s that you don’t cross FDA can­cer czar Richard Paz­dur. Paz­dur is fa­mous for cut­ting com­pa­nies to shreds dur­ing pan­el re­views if they come to the agency with ques­tion­able da­ta af­ter stray­ing from the path he set for them. 

A blunt speak­er, Paz­dur tends to de­liv­er on what he says. When he stood up at AS­CO sev­er­al years ago to say that the break­through ther­a­py des­ig­na­tion was im­por­tant and that the agency would start hus­tling along ac­cel­er­at­ed re­views for can­cer pa­tients, he de­liv­ered on every word — spurring a rev­o­lu­tion in the way can­cer drug tri­als are de­signed and ex­e­cut­ed and in­flu­enc­ing the en­tire field of re­search and de­vel­op­ment.

And now he’s clear­ly un­hap­py with the way the on­col­o­gy R&D world has un­leashed thou­sands of stud­ies in­volv­ing a rapid­ly pro­lif­er­at­ing set of PD-1/L1 check­point ther­a­pies that have cre­at­ed a whole new megablock­buster fran­chise for in­dus­try play­ers to tack­le.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA